Findings presented at the European Association for the Study of Diabetes Annual Meeting in Milan indicate that roughly half of adults with a body mass index between 25 and 26.9 — a range that falls below the threshold for GLP-1 weight-loss drug eligibility — may face cardiovascular risk levels comparable to those who do qualify for such treatment. The study, spearheaded by Karen Hvid at Copenhagen University Hospital in Herlev, Denmark, tracked a cohort of over 313,000 adults living with overweight or obesity across the UK and Denmark. Individuals whose BMI fell between 25 and 26.9 and who also presented with elevated remnant cholesterol, low-grade inflammation, or a combination of both faced a cardiovascular disease risk level comparable to those who qualify for treatment with semaglutide or tirzepatide. Prescribing eligibility remains unaffected by the new findings. The issue brings into focus a broader debate among patients in the United States: whether body mass index thresholds represent an appropriate standard for determining eligibility for medications that insurers cover on a limited basis and that carry high out-of-pocket costs. Two extended population cohorts — the UK Biobank and the Copenhagen General Population Study — formed the foundation of the team's analysis. Those enrolled had a body mass index of 25 or above, a median age of 58, an approximately even split between male and female, and were free from coronary heart disease and diabetes at baseline. During a follow-up period spanning more than a decade, roughly 23,134 participants received a coronary heart disease diagnosis — encompassing heart attacks, bypass procedures, arterial interventions, or death attributed to cardiovascular causes. Roughly 204,850 individuals — around two-thirds of those studied — qualified for GLP-1 treatment under existing weight loss criteria. Among those deemed ineligible, over nine in ten recorded a body mass index falling between 25 and 26.9. Among participants in that range, approximately 44 per cent of the Danish cohort and 48 per cent of the British cohort displayed elevated remnant cholesterol, low-grade inflammation, or a combination of the two. Individuals who were ineligible and carried both markers faced a 41% higher probability of developing cardiovascular disease in Denmark and 47% higher in the UK, relative to ineligible individuals with normal levels. By comparison, qualifying participants faced a 41% and 35% elevated cardiovascular risk respectively, with Hvid noting at the EASD that this group carried a coronary heart disease risk comparable to those already eligible for GLP1-RAs for weight management, yet would be excluded from receiving the drugs under existing guidelines, and that the research supports broadening the prescribing criteria to include them. In the US, regulatory approval for semaglutide (Wegovy) and tirzepatide (Zepbound) as weight-loss treatments applies to adults with a body mass index of 30 or above, or 27 or above when accompanied by at least one weight-related health condition, including elevated blood pressure, abnormal cholesterol levels, or type 2 diabetes. Someone with a BMI reading of 26 is ineligible for that application, regardless of what their laboratory results indicate. Qualified Part D participants in the federal Medicare GLP-1 Bridge program, active from July 1, 2026, to December 31, 2027, are responsible for a monthly copayment of $50 for select GLP-1 medications. To be eligible, individuals must have a body mass index of 35 or above; a body mass index of 30 or above alongside heart failure with preserved ejection fraction, unmanaged hypertension, or chronic kidney disease at stage 3a or beyond; or a body mass index of 27 or above combined with prediabetes, a previous cardiac event or stroke, or symptomatic peripheral arterial disease. The eligibility criteria do not extend to individuals with a BMI under 27. According to a KFF review of Medicare, the $50 copay will not apply toward the Part D deductible or the $2,100 out-of-pocket ceiling in 2026, a distinction that may carry financial weight for beneficiaries with limited incomes. Extending coverage thresholds to a BMI range of 25 to 26.9 would carry cost implications for Medicare, Medicaid, and employer-sponsored health plans. No cost estimates were produced by the researchers, and the findings have not prompted any federal agency to put forward adjustments to the existing thresholds. Two individuals with nearly identical cardiovascular risk profiles may face different access to weight-loss medication and insurance coverage based solely on where their BMI falls relative to the prescription threshold. Those seeking the medication outside sanctioned applications typically encounter out-of-pocket expenses, while most private insurance plans restrict reimbursement to approved indications. The findings were delivered as an observational study at a conference, with no formally peer-reviewed publication yet available. The data reveals that certain ineligible adults share comparable risk characteristics with those who qualify. The findings alone cannot establish whether GLP-1 medications lower cardiovascular risk in that population — only a randomised clinical trial would provide a definitive answer. Because the study drew exclusively from populations in the United Kingdom and Denmark, its results may not capture the racial, ethnic, and socioeconomic diversity found among patients in the United States. The EASD overview omitted details on financial backing and potential author conflicts, information that readers may wish to bear in mind ahead of the complete publication. Residual cholesterol levels can be derived from a routine lipid panel, while a healthcare provider may also assess whether testing for an inflammatory marker like high-sensitivity CRP is appropriate. Proven strategies for reducing cardiovascular risk — such as managing blood pressure, taking cholesterol-lowering drugs, stopping smoking, and staying physically active — are effective regardless of a person's body weight. Purchasing GLP-1 medications through unverified online sources as a means of bypassing eligibility criteria carries recognised risks that consumers are advised to consider. The conference concludes on Oct. 2, with additional GLP-1 cardiovascular findings anticipated before it wraps up.
